Global Oncology Cancer Drugs Market Trend & Segmentation By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy), By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others), By Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2016-26
Published:
January 2020
Report Code:
BWC19381
Available Format:
PDF PDF Icon
Pages:
210

global oncology cancer drugs market bwc19381

COVID-19

We've been tracking the direct impact of COVID-19 on this market, and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Contact our sales team for more details at

Contact Now

Global Oncology/Cancer Drugs Market: Overview

Cancer is a chronic disease group characterized by uncontrolled cell growth. Breast cancer, lung cancer, colorectal cancer, cervical cancer, and thyroid cancer are perhaps the most common types of cancer. The three main types of drugs used for cancer are cytotoxic drugs, targeted drugs, and hormonal drugs depending on their mechanism of action. Due to increased drug approvals and the advent of biosimilar drugs for cancer treatment, the oncology drug market has seen tremendous growth in the recent past. Increasing spending on cancer treatment has also led to increased research and development efforts to develop new highly effective, and least side-effect cancer drugs.

Global Oncology/Cancer Drugs Market Forecast and Trends

The global market for Oncology/Cancer Drugs is anticipated to expand at a 7.2% CAGR. An increase in the incidence of cancer worldwide and a significant increase in government spending on healthcare services facilitate growth in the global market for oncology / cancer drugs. Fatal effects on the use of cancer drugs, however, impede the development of the market. On the other hand, an increase in the number of pipeline drugs and untapped potential offer lucrative opportunities in the industry in emerging countries. The key drivers of the global market for oncology / cancer drugs are an increase in the geriatric population and an increase in alliances and partnerships to promote the production of medicines. However, the rise in cancer prevalence and the increase in healthcare spending have contributed significantly to this market's growth. Rise in the number of pipeline drugs along with high potential from emerging economies will provide lucrative market expansion opportunities during the forecast period. However, adverse drug-related effects hinder the growth of the market.

Growth drivers

Rising incidence of cancer cases across the globe

The increasing burden of cancer is due to several factors, including population growth and aging, as well as the changing prevalence of specific cancer causes linked to social and economic development. Especially true in fast-growing economies, where there is a change from poverty-related cancers and infections to lifestyle-related cancers. It directly drives demand for oncology drugs on the global market with significant growth.

Need for Innovative Drugs and Target Groups

Cancer research organizations are involved in the development of drugs that target cancer cells directly. This factor has recently played a crucial role in the growth of the global market for oncology/cancer drugs. In contrast, the emphasis on biological therapy has recently brought massive revenues to the global market for oncology/cancer drugs.

Restraint

Adverse effects associated with the use of cancer drugs

Despite the improved efficacy and enhanced survival offered by modern treatments, the side effects and long-term sequelae of anti-cancer chemotherapy remain a significant concern for both patients and clinicians.

Global Oncology/Cancer Drugs Market: Drug Class Type

Targeted therapy and chemotherapy segments together accounted for nearly three-fourths of total market shares in 2019 based on drug class type, and are expected to maintain dominance in the cancer drug industry over the forecast period. Conversely, the section of immunotherapy is predicted to be a witness of lucrative growth due to higher survival rates and use-related remission.


Global Oncology/Cancer Drugs Market: Indication

Based on the indication, it estimated that the lung cancer segment would record a significant rate of growth from 2020 to 2026 due to a considerable increase in prevalence worldwide. On the other hand, the segments of kidney, breast, and prostate cancer together have contributed to the largest segment of total market share in 2019 and are projected to continue to lead during the forecast period.

Global Oncology/Cancer Drugs Market: Regional insights

Due to the high adoption rate of cancer drugs, North America was the leading contributor to the worldwide market in 2019. However, during the forecast period, Asia-Pacific is expected to grow due to an increase in disposable income, a rise in research, development and innovation activities, and an increase in awareness of various cancers. Asia-Pacific is projected to grow at the highest rate, accompanied by North America, from 2019 to 2026. Due to a vast population base and modern health care facilities. North America and Europe accounted for almost three-fourths of total market share in 2019 and will continue to dominate by 2026 due to the increased awareness of advanced therapies, sedentary growth in lifestyle, and ease of access to premiere chemotherapy treatments.


The objective of the Study:

·         To analyze and forecast the global Oncology/Cancer Drugs market size of the market in terms of value.

·         To examine the careful market segmentation and forecast the market size, in terms value, based on the region by segmenting the Global Oncology/Cancer Drugs market into five regions, namely, North America, Europe, Asia Pacific, Middle East & Africa and South America.

·         To outline, categorized, and forecast the global Oncology/Cancer Drugs market based on the drug class type and indication.

·   To examine competitive developments like technological advancement, services, and regulative framework within the global Oncology/Cancer Drugs Market.

·     To highlight the impact analysis of the factors affecting the market dynamics such as drivers, restraints, opportunities, and challenges.

·      To strategically profile the key players and comprehensively analyze their market shares along with detailing the competitive landscape for market leaders.

Scope of the Report

By Class Type

·         Chemotherapy

·         Targeted Therapy

·         Immunotherapy (Biologic Therapy)

·         Hormonal Therapy

By Indication

·         Lung Cancer

·         Stomach Cancer

·         Colorectal Cancer

·         Breast Cancer

·         Prostate Cancer

·         Liver Cancer

·         Esophagus Cancer

·         Cervical Cancer

·         Kidney Cancer

·         Bladder Cancer

·         Other Cancers

By Region: 

·         North America

·         Europe

·         Asia Pacific (APAC)

·         Latin America

·         Middle East & Africa

Competitive Landscape

·         AbbVie Inc.

·         Astellas Pharma, Inc.

·         AstraZeneca PLC

·         Bristol-Myers Squibb Company

·         Celgene Corporation

·         F. Hoffmann-La Roche Ltd.

·         Johnson & Johnson (Janssen Global Services, LLC,)

·         Merck & Co., Inc.

·         Novartis AG

·         Pfizer Inc.

·         Other Prominent Players

Business Questions Answer by the Report

·         How will the market drivers, restraints, and opportunities affect the market dynamics?

·         What will be the market size in terms of value and volume and market statistics with a detailed classification?

·         Which segment dominates the market or region, and one will be the fastest-growing, and why?

·         A comprehensive survey of the competitive landscape and the market participant players

·         Analysis of strategy adopted by the key player and their impact on other players.

Customization Scope for the Client

Client satisfaction is our first and last priority, and that’s why BlueWeave Consulting offers customization according to Company’s specific needs. The following customization options are available for the report:

Additional Company Information

·         With five additional company detail analysis

·         Additional country analysis

·         Detailed segment analysis

Why Choose us

  • 24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Coustom Research Service

    Ask the Analyst to customize an exclusive study to serve your research needs.

  • Quality & Accuracy

    offers best quality reports based on various authentic and accurate data findings.

  • Data Visualization

    As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization

  • Information security

    We never share your personal and confidential information. Your personal information is safe and secure with us.